Advs. David Schapiro, Daniel Marcovici Moshe Pasker represented Telrad Networks Ltd. in its purchase of Mermanet Organization and Project Management Ltd. for NIS 102 million. Telrad was represented in its negotiations with the banks for the purpose of raising NIS 78 million, part of the amount required for the transaction.
Advs. Daniel Marcovici and Shai Margalit represented the Eldar Group in a NIS 65 million investment by the Arbel Fund.
Different publications concerning the agreement can be viewed here (Hebrew):
The panel, moderated by Zvi Gabay, a former Commissioner of the Securities Authority Enforcement, referred to a series of Administrative Enforcement issues. Excerpts from the panel were published in the "Echad Haam" magazine of the Public Companies Association, distributed by the Globes newspaper.
Advs. Daniel Marcovici, David Schapiro, Amir Kolton and Eric Spindel acted for JP Morgan as the lead underwriter of a private placement to Israeli and foreign institutional investors of senior secured notes in the aggregate amount of $800,000,000, issued by B Communications Ltd. (the controlling shareholder of Bezeq (TASE: BZEQ), Israel’s largest telecommunications provider). The notes are secured through placement of a lien on certain assets of the issuer, including its controlling shareholding in Bezeq. The notes will be registered for trading on the Tel-Aviv Stock Exchange's platform for trading by institutional investors known as "TACT-Institutional". This offering was unique and unprecedented in Israel, both in terms of size and complexity, it having required various regulatory approvals, including from the Israel Securities Authority, the Ministry of Communications and the Prime Minister of the State of Israel, the Israeli Tax Authority and the Tel-Aviv Stock Exchange.
Advs. Barry Levenfeld, Eric Spindel, Avigail Frisch and Noam Enk represented Aegis for Alcobra Ltd.'s initial public offering on Nasdaq. Alcobra Ltd., headquartered in Israel, is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug to treat Attention Deficit Hyperactivity Disorder.